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Abstract The application of autologous dermal fibroblasts
has been shown to improve burn wound healing. However, a
major hurdle is the availability of sufficient healthy skin as a
cell source. We investigated fetal dermal cells as an alternative
source for cell-based therapy for skin regeneration. Human
(hFF), porcine fetal (pFF) or autologous dermal fibroblasts
(AF) were seeded in a collagen–elastin substitute (Novomaix,
NVM), which was applied in combination with an autologous
split thickness skin graft (STSG) to evaluate the effects of
these cells on wound healing in a porcine excisional wound
model. Transplantation of wounds with NVM+hFF showed
an increased influx of inflammatory cells (e.g., neutrophils,
macrophages, CD4+ and CD8+ lymphocytes) compared to
STSG, acellular NVM (Acell-NVM) and NVM+AF at post-
surgery days 7 and/or 14. Wounds treated with NVM+pFF
presented only an increase in CD8+ lymphocyte influx. Fur-
thermore, reduced alpha-smooth muscle actin (αSMA) ex-
pression in wound areas and reduced contraction of the
wounds was observed with NVM+AF compared to Acell-
NVM. Xenogeneic transplantation of NVM+hFF increased
αSMA expression in wounds compared to NVM+AF. An
improved scar quality was observed for wounds treated with
NVM+AF compared to Acell-NVM, NVM+hFF and NVM+
pFF at day 56. In conclusion, application of autologous fibro-
blasts improved the overall outcome of wound healing in
comparison to fetal dermal cells and Acell-NVM, whereas
application of fetal dermal fibroblasts in NVM did not im-
prove wound healing of full-thickness wounds in a porcine
model. Although human fetal dermal cells demonstrated an
increased immune response, this did not seem to affect scar
quality.
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Introduction
Deep partial and full-thickness burn wounds often result in
hypertrophic scars. Although burn wound care has improved
over the years, scarless wound healing is still beyond reach.
One of the causes that lead to hypertrophic scarring of burn
wounds is partial or complete loss of the dermis. The use of
collagen-based dermal substitutes to replace the lost and/or
damaged dermis has been shown to improve the outcome of
wound healing. Examples of this have been described by
Bloemen et al. (2010) and Ryssel et al. (2008), who showed
that transplantation of acellular collagen-based dermal substi-
tutes with split thickness skin grafts (STSG) on top of full-
thickness burn wounds improved scar quality. A smoother
skin (less relief) and better pliability were observed, even
12 years post-surgery, compared to the control which received
only STSG (Bloemen et al. 2010). Despite improved scar
quality when using acellular dermal substitutes, the optimal
result of full skin regeneration is still not achieved. Cell-based
therapy is one of the strategies that may further improve skin
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regeneration. Indications for this have been found in the use of
autologous dermal cells which were shown to improve the
wound healing and/or scar formation of burn wounds. Lamme
et al. (2000) demonstrated in a porcine full-thickness wound
model that addition of autologous dermal cells to a dermal
substitute can reduce scarring in vivo, as improved scar
quality in terms of reduced redness, contraction and relief
was observed compared to the acellular dermal substitute.
Furthermore, dermal substitutes seeded with autologous
dermal cells also significantly reduced alpha smooth muscle
actin (αSMA) expression in the wound area compared to
acellular dermal substitutes. Expression of αSMA is indica-
tive of the presence of myofibroblasts and contraction in scar
tissue of burn wounds. Improved healing of burn wounds after
application of substitutes containing autologous dermal cells
was also shown clinically in a case report by Wisser and
Steffes (2003).
In contrast to allogeneic cells, the advantage of using au-
tologous cells is that they will not elicit a host versus graft
(rejection) reaction upon transplantation. On the other hand,
one of the major hurdles with autologous cell-based therapies
is to obtain sufficient cells in a limited amount of time. Espe-
cially, patients with extensive burn wounds have limited avail-
ability of healthy skin for harvesting autologous dermal cells.
Moreover, expansion of the autologous cells to a sufficient
number may take up to 3 weeks (Hata 2007; Tan et al. 2014)
and is associated with high costs. To overcome these hurdles,
an alternative cell source is sought for use in cell-based ther-
apies. One of the cell types that has been proposed are mes-
enchymal stem cells (MSCs). MSCs are known for their
multipotency (Dominici et al. 2006; Maxson et al. 2012). It
has been reported that direct transplantation ofMSCs, or seed-
ed in dermal substitutes, can have beneficial effects on wound
healing in vitro and in vivo (Laverdet et al. 2014; Maxson
et al. 2012). An in vivo animal study by Liu et al. (2008)
showed reduced wound contraction, improved wound healing
and better vascularization and re-epithelialization after trans-
plantation of collagen–glycosaminoglycan substitutes seeded
with autologous bone marrow-derived MSCs in partial thick-
ness burn wounds using a porcine model. Several tissues can
serve as a source for MSCs, such as bonemarrow, fat, gingiva,
and dermis, as well as fetal tissue (umbilical cord, placenta)
(Laverdet et al. 2014). However, the accessibility, cell number
and availability can vary between the different tissues.
Fetal dermal cells which have MSC characteristics
(Chinnici et al. 2014; Tan et al. 2014; Young et al. 2001) have
been indicated as a promising cell source for cell-based ther-
apy for skin regeneration. An essential advantage is that fetal
skin cells have a better regenerative and higher proliferative
capacity compared to adult cells (Ferguson et al. 1996; Kishi
et al. 2012; Rolfe and Grobbelaar 2012; Yates et al. 2012).
Fetal wounds are known to heal faster, and with nearly no
scarring up to the middle of the third trimester (Ferguson
et al. 1996; Satish and Kathju 2010). They also seem to have
a higher recovery rate after cryopreservation compared to
adult cells (Applegate et al. 2009; De Buys Roessingh et al.
2006). In addition, fetal cells have a low immunogenicity
which is an advantage with respect to allograft transplantation
and rejection. MHC molecules play an important role in this,
since MSCs (Ryan et al. 2005), but also fetal dermal cells
(Chinnici et al. 2014) (<14 weeks of gestation for humans)
have a very limited expression of MHC class II molecules on
their cell surface. The expression of MHC class II molecules
remains absent after culturing of fetal dermal cells until pas-
sages 21–28 (Chinnici et al. 2014; Hohlfeld et al. 2005). Fur-
thermore, MSCs have been shown to modulate CD4+ and
CD8+ T lymphocyte responses in in vitro co-cultures (Barry
et al. 2005; Ryan et al. 2005). In vitro studies showed, for
example, that MSCs inhibited T lymphocyte proliferation, in-
creased CD4+ CD25+ T lymphocyte (Tregs) populations, sup-
pressed CD4+ and CD8+ lymphocyte activity and created an
immunosuppressive environment (Barry et al. 2005; Le Blanc
2003; Ryan et al. 2005).
All these advantages might allow the creation of a well-
characterized fetal skin cell bank which could be used for cell-
based therapies. Development of such an Boff-the-shelf^ prod-
uct would remedy the cell number deficiency and decrease
culture time for cell-based dermal substitutes. Applegate and
colleagues have already investigated the establishment of a
fetal skin cell bank (Applegate et al. 2009; De Buys Roessingh
et al. 2006). They were able to create several million con-
structs out of just one 4 cm2 fetal dermal tissue biopsy
(Applegate et al. 2009; Hohlfeld et al. 2005). Moreover, they
used constructs with fetal skin cells for burn wounds in chil-
dren and observed faster wound healing and less scarring
(Hohlfeld et al. 2005). However, fetal constructs were topical-
ly administered and refreshed every dressing change. There
are two explanations for the results of this study: migration of
fetal dermal cells into the wound bed, or that these cells only
provided growth factors, chemokines and cytokines by para-
crine signaling (Chen et al. 2008; Gnecchi et al. 2008;
Hocking and Gibran 2010). Furthermore, the burn wounds
of the children treated with the fetal dermal constructs seemed
relatively small, and were possibly not completely full-
thickness wounds (Scott and Tredget 2005). Therefore, the
beneficial effects of dermal substitutes containing fetal dermal
cells for the application in full-thickness (burn) wounds re-
main to be elucidated.
The aim of our study was to investigate the effects of fetal
dermal cells on wound healing and scarring of full-thickness
wounds. A porcine full-thickness wound model was used to
study the effect of a porcine collagen-based dermal substitute
(Novomaix, NVM) seeded with human (xenogeneic) or por-
cine (allogeneic) fetal dermal cells in combination with a
STSG onwound healing and scar formation. These treatments
were compared to NVM seeded with autologous dermal
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fibroblasts. We investigated the wound healing and scar char-
acteristics, as well as the inflammatory response of these dif-
ferent treatment modalities.
Materials and methods
Fetal and autologous dermal fibroblast isolation
Human fetal fibroblasts
Human fetal fibroblasts were isolated from fetal skin (derived
from extremities) after pregnancy termination; the age of the
fetus was 12 weeks (one donor). Fetal skin was obtained with
the informed and written consent of the pregnant woman.
Skin tissue was washed with phosphate-buffered saline
(PBS) and cut into small pieces for enzymatic treatment. Tis-
sue was digested using 0.25 % (w/v) collagenase A and
0.25 % (w/v) dispase II (Roche Diagnostics, France) in PBS
for 1–2 h at 37 °C under agitation (van den Bogaerdt et al.
2002). Digested tissue was washed with PBS containing 1 %
fetal calf serum (FCS) (HyClone FetalClone III; Thermo
Scientific, Etten-Leur, The Netherlands) and filtered over an
open filter chamber (Beldico, Duiven, The Netherlands) to
remove large tissue debris particles. Cells were pelleted by
centrifugation for 10min at 385g. Cell pellets were resuspend-
ed in fibroblast culture medium (FBM) which consisted of
DMEM (Gibco, Paisley, UK) supplemented with 10 % v/v
FCS, 1 mM L-glutamine, and the antibiotics penicillin
(100 IU/mL) and streptomycin (100mg/mL) (Gibco). The cell
suspension was filtered through a 70-μm cell strainer (Falcon;
Becton Dickinson, Mountain View, CA, USA) to remove any
remaining tissue debris. Cells were pelleted (267g, 10 min),
resuspended in FBM and seeded with a cell density of 3×106
per 175-cm2 tissue culture flask (1.7×104 per cm2). From
human adult dermis, an average of 1×106 cells/g tissue can
be obtained and for human (and porcine) fetal skin an average
of 20×106 cells/g tissue. Cell doubling times for human adult
fibroblasts is 4.6 days and for fetal fibroblasts 2.3 days. Cells
were cultured until a sufficient amount of cells was obtained.
Cells of passages P1–P4 were used in the experiment.
Porcine fetal and autologous fibroblasts
For the isolation of porcine fetal dermal cells, unborn piglets
were isolated from a 60-day pregnant Yorkshire pig. Skin was
taken from flanks of the piglets. For the isolation of autolo-
gous (adult) fibroblasts, two sheets (5×20 cm, 0.3 mm) of
split thickness autologous skin were taken from the back of
the animals (from animals in which later full-thickness
wounds were created) with an electrical dermatome. This
was performed 1 week before transplantation. Isolation of
the porcine autologous and fetal fibroblasts was performed
as described above in ‘human fetal fibroblasts’. Porcine fetal
and autologous fibroblasts were cultured and seeded into
Novomaix (NVM) dermal substitutes.
Cell characterization
hFF, pFF and AF were seeded onto glass slides with a density
of 50,000 cells/slide. After 2–3 days of culture, cells were
fixed with 4 % formaldehyde for 15 min at RT. Cells of pas-
sages P2–P5 were used for immunohistochemistry. Cells were
pretreated with 0.5 % Triton X-100. Next, cells were stained
for heat shock protein 47 (HSP47), which is used as a fibro-
blast marker, and αSMA for 1 h at RT (see Table 4 for
antibodies and dilutions). Subsequently, slides were incubated
for 45 min at RT in the dark using goat-anti-mouse Alexa488
(1:500, A21424; Life Technologies, VWR, Amsterdam,
The Netherlands) and goat-anti-mouse Alexa555 (1:500,
A11017; Life Technologies) respectively as secondary
antibodies.
Dermal substitute Novomaix
Novomaix (NVM) (Matricel, Herzogenrath, Germany)
collagen–elastin scaffolds (average pore size 100 μm)
were used as dermal substitutes. The highly purified col-
lagen and elastin fibers of this scaffold are of porcine
origin. Characteristics and features of NVM have been
described previously by Boekema et al. (2014). Three
days before surgery, NVM was cut into pieces of 3.5×
3.5 cm and prewetted with FBM. Human (hFF) or porcine
(pFF) fetal or autologous (AF) fibroblasts were seeded on
top of the dermal substitutes with a cell density of 5×105
fibroblasts/cm2. The cell suspension was absorbed by the
dermal substitute. Two hours of incubation at 37 °C was
implemented to allow fibroblasts to attach to NVM, and
thereafter 20 mL of FBM culture medium containing
65 μg/mL vitamin C (Sigma Aldrich, Steinheim, Germa-
ny) was added per dermal substitute. Culture medium was
replaced every day with medium with freshly added vita-
min C until the day of surgery. The acellular NVM (Acell-
NVM) was treated similar to the cell-seeded NVM, only
all procedural steps were without cells. Acellular and cell-
seeded substitutes were transplanted on excised full-
thickness wounds on the day of surgery. Treatments were
randomly appointed to the wounds per animal as de-
scribed in Table 1. Two wounds per animal received the
same treatment. The treatment with STSG alone is com-
parable to the treatment that is standard in the clinic. Fur-
thermore, addition of AF to the dermal substitute NVM
was also used as a control because these cells have al-
ready been shown to improve scar quality.
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Animal experiments, operative and bandaging procedures
The institutional Animal Experiments Committee of the VU
University Medical Center Amsterdam, The Netherlands, ap-
proved the experimental protocols according to governmental
and international guidelines on animal experimentation. The
pigs received a week’s acclimatization period before the start
of the experiment. The pigs were individually housed, fed
twice a day and had access to water ad libitum. In total, six
female Yorkshire pigs were used. Animals had an average
body weight of 31 kg at the start of the experiment and an
average of 67 kg at the end.
Animal sedation/anesthesia/analgesia
Twenty minutes before the start of the surgical procedure,
the animals were sedated with a combination of Ketamine
10 mg/kg, Dormicum (Midazolam) 0.5 mg/kg and Atro-
pine 0.5–1.0 mg by intramuscular (i.m.) injection. Anes-
thesia during the tattoo, biopsy, and bandage-change pro-
cedures was induced and maintained by 35 % O2, 65 %
NO2 and 1.5–2.5 % Isoflurane via a mouth cap. Analgesic
Novum 20 (Meloxicam, 0.04 mg/kg) was administered
i.m.
Before the surgery (creation of full-thickness wounds,
application of dermal substitutes and STSG transplanta-
tions), full anesthesia was induced using Etomidate lipidor
via intravenous (i.v.) injection (sedation), Dormicum
(Midazolam) 15 mg, and as analgesia Fentanyl 200 μg
and muscle relaxant Pavulon (Pancuronium bromide)
6 mg (i.v.). During surgery, the anesthesia was maintained
by i.v. injection of Dormicum 0.5 mg/kg/h, Fentanyl
6.5 μg/kg/h and Pavulon 0.27 mg/kg/h. Furthermore, arti-
ficial respiration with 45–50 % O2 and 1.5–2.5 %
Isoflurane was provided when the animals received full
anesthesia. Vital functions such as CO2 expiration concen-
tration, blood gas values, heart rate and temperature were
monitored during surgery. Direct post-operative analgesia
was administered by i.m. injection of Buprenorphine
0 .3 mg. Af te r the surg ica l p rocedure , 5 μg /kg
Buprenorphine was administered at least once, or every
10–12 h when there was indication of pain. Metacam was
orally administered once a day for a period of 2 weeks.
Surgical procedure
Surgical procedures of these animal experiments were per-
formed using the porcine excisional wound model described
by Middelkoop et al. (2004). In short, 1 week before the cre-
ation of the full-thickness wounds, a grid of 7×7 cm squares
was tattooed on both flanks of the pigs. This grid is used to
correct for the growth of the animal. At the day of surgery,
seven full-thickness, 2.7-mm-deepwounds of 3×3 cm squares
were created on each flank of the pig. Autologous STSGs
(0.3 mm thickness) were obtained from the wound sites
using an electrical dermatome (Humeca, Enschede,
The Netherlands). STSGwere meshed (Humeca) in a 1:3 ratio
and kept moisturized in sterile PBS-soaked gauzes until use.
Wounds were excised with a scalpel to full-thickness (until the
subcutaneous fat layer). Twelve of 14 full-thickness wounds
per animal were transplanted with a dermal substitute (NVM),
with or without cells, and covered with a meshed STSG. Two
of the 14 wounds per animal received only an STSG. Dermal
substitutes and STSGs were fixed with staples (3M, Delft,
The Netherlands). The different treatments were randomized
over the seven wounds on each flank. Two wounds per animal
received the same treatment. Three of the seven wounds per
flank received other treatments, which will not be described in
this article. Therefore, the number of wounds described in this
article is in total 48. Wounds were dressed with adhesive
Alleveyn (gentle border 10×10 cm; Smith & Nephew, Hull,
UK) to protect against mechanical trauma and contamination.
Sterile gauzes (45×70 cm) were used to cover the Alleveyn
bandages, and were fixed with adhesive bandage Curafix
(Lohmann & Rauscher, Neuwied, Germany) and the elastic
stocking Tubigrip was used (Klinion; Mediq Medeco, Oud-
Beijerland, The Netherlands).
Macroscopic wound evaluation and dressing changes
Wounds were macroscopically evaluated during dressing
changes at 4, 7, 14, 21 days, and at the end of the experiment
at 56 days post-surgery. Macroscopic evaluation of the
wounds was performed by 2–3 independent trained observers
who were blinded for the treatment. Parameters used in the
macroscopic evaluation were obtained and adjusted from the
observer part of the Patient and Observer Scar Assessment
Scale (POSAS). The POSAS is a validated method used for
Table 1 Treatment modalities of
cell-seeded and control treatments Treatment Abbreviation treatment Total number of wounds
Split thickness skin graft STSG 12
Novomaix (NVM) (acellular) + STSG Acell-NVM 12
Human fetal dermal fibroblasts + NVM + STSG NVM+hFF 6
Porcine fetal dermal fibroblasts + NVM + STSG NVM+pFF 6
Autologous fibroblasts + NVM + STSG NVM+AF 12
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scar evaluation in patients in the clinic (Draaijers et al. 2004;
van der Wal et al. 2012). Wounds were evaluated for graft
take, wound color, wound closure, wound thickness, skin
smoothness and wound pliability (Table 2). At the end of the
experiment (day 56), each wound was given an overall ob-
server score for scar quality (Table 2). This scar quality score
was based on all scored parameters (such as contraction, red-
ness, thickness and relief) at day 56.
Digital pictures of the wounds were taken on days 0,
4, 7, 14, 21 and 56. To measure contraction of the
wound at days 0, 21 and 56, the wound edges and
tattoo grid were traced onto a transparent sheet. Con-
traction was determined by planimetry (NIS Elements,
v.3.1; Nikon, Badhoevedorp, The Netherlands) and
corrected for the growth of the animal by calculating
the wound area as a ratio of the area of the tattoo grid.
This was subtracted from the original wound/tattoo grid
area relation of day 0. Contraction is expressed as per-
centage contraction of the wound compared to day 0
which was set at 0 % (no contraction). The measure-
ment of wound contraction is explained in Lammers
et al. (2011: fig. 2). Two punch biopsies (Ø 4 mm) of
the wounds were taken on days 4, 7, 14 and 21, in a
systematic order. At the end of the experiment (day 56),
the animals were euthanized with 30 mL pentobarbital
sodium i.v., and subsequently a large biopsy across the
center of the wound was taken. Wound biopsies were
fixed in Kryofix (48 % ethanol, 7 % polyethylene gly-
col (PEG)-300) and stored at 4 °C, or snap-frozen in
liquid nitrogen and stored at −80 °C until further
analysis.
Microscopic wound evaluation
Kryofixed tissue biopsies were dehydrated, embedded in par-
affin and cut into sections of 5-μm thickness. For
( immuno)his tochemical s ta in ings, sec t ions were
deparaffinized and rehydrated. A hematoxylin (Mayers;
DAKO, Glostrup, Denmark) and eosin (Sigma-Aldrich)
staining was performed to evaluate dermal substitute pres-
ence, epidermis, number of foreign body giant cells (FBGC)
and granulation tissue thickness (Table 3). Granulation thick-
ness was measured using digital image analysis (NIS Ele-
ments, v.3.1).
Presence of myofibroblasts in wound tissue sections
was assessed by αSMA expression using an antibody
against αSMA (Table 4). Sections were stained with
an antibody directed against CD31 to study the presence
of blood vessels (Table 4). Neutrophils were stained
using an antibody directed against MPO (Table 4). To
investigate the treatment effects on the immunological
response, frozen sections (5 μm) were stained for im-
mune cells: macrophages (CD163), CD4+ and CD8+
lymphocytes (Table 4).
Slides were incubated with secondary antibodies
BrightVision Poly-HRP anti-mouse or anti-rabbit (Immuno-
logic, Duiven, The Netherlands). The substrate 3,3′-Diamino-
benzidine (DAB) (Immunologic) was used to visualize the
staining. Tissue sections were counterstained with hematoxy-
lin.We determined the wound area positive forαSMA expres-
sion by selection of the DAB signal in the tissue using NIS
Elements (Nikon). The area of the DAB signal was expressed
as a fraction of the total wound area. Immune cells were
scored for presence on a scale of 0 (not present) to 5 (severe
influx). All microscopic analyses were performed blinded to
the treatment and scored by at least two trained observers.
Statistics
All statistical analyses were performed with SPSS
(v.21.0 MS Windows; SPSS, Chicago, IL, USA). Statis-
tically significant differences between treatment groups
were determined by using the nonparametric Kruskal–
Wallis test. A two-tailed Mann–Whitney U test was
used as a post hoc test. A p value of <0.05 was con-
sidered statistically significant. Graph bars represent the
mean and the standard deviation per treatment.
Table 2 Parameters for macroscopic wound evaluation
Parameter Score Description
Graft take Percentage (%) of vital graft from total graft I.e., viability of the graft (pink color) and adherence
to the wound bed (%)
Wound closure Percentage (%) of total wound area that is
covered by epithelium
Re-epithelialization of the wound area
Wound color Scale 0 to 5 Compared to unaffected skin (pink, =0), +5=purple/red
Wound thickness (depth) Scale −5 to 5 Level compared to normal epidermis level (=0),
−5=deep wound, +5=raised wound
Distortion
(compared to original wound shape)
Scale 0 to 5 0=original size wound square, 5=severe star-shaped
wound area
Observer score (scar quality) Scale 1 to 10 Compared to unaffected skin (1=unaffected skin)
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Results
Mesenchymal stem cell characteristics of fetal dermal cells
The presence of mesenchymal stem cells in a fetal dermal cell
population and their characteristics were assessed by flow
cytometric analysis and differentiation capacity. Human fetal
dermal cells were positive for CD105, CD73 and CD90, and
were negative for CD14, CD31, CD34, CD45, CD79a and
HLA-DR (data not shown). Both human and porcine fetal
dermal cells were able to differentiate into osteoblasts,
chondrocytes and adipocytes (data not shown). These results
meet the criteria as defined by Dominici et al. (2006). Pheno-
typical characterization of adult MSCs derived from different
sources has been described by van den Bogaerdt et al. (2009).
AF, hFF and pFF cultured on glass slides showed similar
staining of the cytoplasm for HSP47 (Fig. 1d-f). αSMA ex-
pression in these cells was also similar for AF and pFF; how-
ever, the αSMA expression in hFF seemed slightly lower
(Fig. 1a-c). αSMA expression by these cells was represented
as a stress fiber phenotype.
Autologous fibroblasts in collagen-based dermal
substitutes improved scar quality
Scars of the differently treated wounds were macroscopically
evaluated 56 days post-surgery using an adapted POSAS scar
assessment scale (Table 2). A lower score represents a better
scar quality, indicating closer similarity to unaffected skin.
Figure 2a illustrates a macroscopic view of the scars at 56 days
post-surgery. Wounds transplanted with NVM+hFF, NVM+
pFF, Acell-NVM or STSG demonstrated a more star-shaped
scar (distortion) compared to wounds treated with NVM+AF.
The overall observer scores (scar quality) of the NVM+hFF
and NVM+pFF group were similar to STSG and Acell-NVM
treatment (Fig. 2b). Wounds treated with NVM+AF showed
an improved scar quality compared to Acell-NVM, NVM+
hFF and NVM+pFF at post-surgery day 56 (Fig. 2b). No
differences of other macroscopic (Table 2) and microscopic
(Table 3) evaluation scores were observed between the differ-
ent treatments.
Collagen-based dermal substitutes seeded with autologous
fibroblasts reduced scar contraction and αSMA
expression
Excessive wound contraction is a frequently encountered
characteristic of burn wound scars. Contraction of the
wound was macroscopically evaluated (see description
above), but also determined by planimetric analysis at
days 21 and 56 post-surgery (Fig. 3a). Increased con-
traction was noted for wounds treated with NVM+hFF
versus Acell-NVM at day 21. Full-thickness wounds
transplanted with NVM+hFF or NVM+pFF showed sta-
tistically significantly more contraction compared to
NVM+AF at post-wounding days 21 and 56 (Fig. 3b).
A lower wound contraction was only observed in
wounds transplanted with NVM+hFF compared to
NVM+pFF at day 21. Furthermore, addition of AFs to
a dermal substitute reduced contraction of full-thickness
Table 4 Primary antibodies
Primary antibody Clone Dilution producer
Anti - αSMA 1A4 1:500 DAKO, Glostrup, Denmark
Anti - CD31 SP38 (M3380) 1:150 Abbiotec, San Diego, CA, USA
Anti - MPO A0398 1:1200 DAKO, Glostrup, Denmark
Anti - CD163 MAC2.48 1:1000 IQproducts, Groningen, The Netherlands
Anti - CD4 MIL17 (MCA1749) 1:50 AbD Serotec, Puchheim, Germany
Anti - CD8 MIL12 (MCA1223) 1:100 AbD Serotec, Puchheim, Germany
Anti - HSP47 M16.01A1 1:500 Enzo Life Sciences, Raamsdonksveer, The Netherlands
Table 3 Parameters for
microscopic wound evaluation Parameters Score
Presence of dermal substitute Scale 0 to 3 0=no dermal substitute remnants,
3=intact dermal substitute structure
Epidermis Scale 0 to 3 0=no epidermis, 3=hyperproliferation
of keratinocytes
Foreign body giant cells
(FBGC)
Number of FBGC cells in
wound area of the tissue section
Thickness granulation tissue Micrometer (μm) Distance from start of dermis to
subcutaneous fat layer
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wounds in comparison Acell-NVM (day 21 and 56).
Overall, contraction increased over time.
The presence of myofibroblasts in the wound area was
analyzed by immunohistochemical staining of αSMA at day
14. Figure 3b illustrates that a statistically significantly larger
fraction of the total wound area was αSMA positive in
wounds transplanted with NVM+hFF or pFF compared to
NVM+AF. Wounds of NVM+hFF showed a clear αSMA-
positive expression in the granulation tissue (Fig. 3c), while
αSMA-positive expression was significantly less in wounds
of NVM+AF (Fig. 3d) at day 14. Induction of αSMA expres-
sion in the wound area tended to be less in wounds treated
with NVM+pFF compared to NVM+hFF (p=0.055). It is
noteworthy that the addition of AF to NVM significantly
reduced the αSMA expression in the wound area compared
to Acell-NVM at day 14.
Increased influx of inflammatory cells
after transplantation of fetal fibroblasts
NVM seeded with hFFs or pFFs did not improve the macro-
scopic scar characteristics or scar quality compared to the
Acell-NVM treatment. Since inflammation can influence scar
formation, the presence of inflammatory cells such as neutro-
phils, macrophages, CD4+ and CD8+ T lymphocytes in the
wound area was investigated.
Neutrophils and macrophages play an important role in clear-
ing of infections and tissue debris (e.g., dead cells). An increased
Fig. 1 Cell characterization by
αSMA and HSP47 expression in
hFF, pFF and AF (porcine), cells
cultured on glass for 2–3 days and
stained for DAPI (blue), HSP47
(green) and αSMA (red). a–c All
cell sources showed a number of
αSMA positive cells in the cell
population. All αSMA positive
cells showed stress fiber
formation. d–f HSP47 stained the
cytoplasm of all cells, indicating
their fibroblastic phenotype. Scale
bars 50 μm
Fig. 2 Macroscopic evaluation of treated wounds at day 56. a
Representative photographs of wounds per treatment. b Scar quality
(overall observer score) as determined by scoring parameters of the
POSAS scale. Scar quality was improved (represented by lower scores)
in wounds transplanted with NVM+AF (n=12 wounds) compared to
Acell-NVM (§, n=12 wounds), NVM+hFF (*, n=6 wounds) and
NVM+pFF (#, n=6 wounds). Statistical significance is indicated by
symbols (Mann–Whitney U test, p <0.05). STSG Split thickness skin
graft, Acell-NVM Novomaix+STSG, NVM+hFF Novomaix containing
human fetal fibroblasts + STSG, NVM+pFF Novomaix containing
porcine fetal fibroblasts + STSG, NVM+AF Novomaix containing
autologous fibroblasts +STSG
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influx of neutrophils was observed upon transplantation of
NVM+hFF compared to all the other treatments at days 7 and
14 (Fig. 4a). The influx of neutrophils remained at the same level
until day 14 in the NVM+hFF group. Wounds treated with
NVM+pFF showed a much lower influx of cells than NVM+
hFF (days 7 and 14). In addition, NVM+pFF showed a lower
neutrophil influx compared toAcell-NVMandNVM+AF at day
7. Furthermore, statistically significant lower neutrophil scores
were observed in wounds treated with NVM+AF compared to
NVM+hFF at both post-surgery days 7 and 14 (Fig. 4a).
Macrophage scores in Fig. 4b illustrate that full-thickness
wounds transplanted with NVM+hFF showed statistically sig-
nificant higher macrophage influx compared to Acell-NVM
(days 7 and 14), NVM+pFF (day 7) and NVM+AF (day 14).
No differences in macrophage influx were detected when
NVM+pFF and NVM+AF were compared with Acell-NVM
at day 14. Overall, a declining trend in macrophage score was
observed for all treatments at day 14 versus day 7, except for
the NVM+pFF group.
One of the most important issues with allogeneic and xe-
nogeneic transplantation is the rejection of graft cells by the
receiver. Both CD4+ and CD8+ lymphocytes play a role in this
process. Especially, cytotoxic CD8+ lymphocytes are able to
recognize foreign MHC molecules. Full-thickness wounds
transplanted with NVM+hFF induced the influx of CD4+
and CD8+ lymphocytes in comparison to Acell-NVM and
NVM+AF at days 7 and 14 post-surgery (Fig. 5). Enhanced
influx of CD4+ lymphocytes was observed for NVM+hFF
compared to NVM+pFF at day 14 (Fig. 5a, b). Remarkably,
CD4+ lymphocyte scores were reduced for all treatment
groups at day 14, except for the hFF group. The CD4+ lym-
phocyte score for NVM+hFF treatment remained at the same
level as day 7. This suggests that the CD4+ lymphocyte re-
sponse is prolonged whenwounds are transplanted with NVM
containing hFF. Besides an induction in the influx of CD4+
lymphocytes within the NVM+hFF group, an elevation in the
CD8+ lymphocyte influx was also noticed. Both NVM+hFF
and NVM+pFF groups induced the CD8+ lymphocyte influx
Fig. 3 Wound contraction and αSMA+ myofibroblasts in the wound
area. a Planimetric analysis of wound area to determine wound
contraction at day 21 and day 56. Contraction is expressed as
percentage contraction of total wound area. NVM+AF (n=12) showed
a reduction in the contraction of the wound compared to Acell-NVM (¶,
§, n=12), NVM+hFF ($, *, n=6) and NVM+pFF (†, #, n=6). Statistical
significance is indicated by symbols (Mann–Whitney U test, p<0.05). b
An immunohistochemical staining forαSMAwas performed to detect the
presence of myofibroblasts in the wound at post-surgery day 14. αSMA
expression of myofibroblasts was calculated as fraction of the wound
area. Wounds transplanted with hFF showed an increased expression of
αSMA in the wound area compared to NVM+AF (*) at day 14. NVM+
AF showed a reduced αSMA expression in the wound in comparison
with Acell-NVM (§), NVM+hFF (*) and NVM+pFF (#). c, d Represen-
tative pictures of wound tissue sections stained for αSMA (DAB, in
brown) at day 14. Full-thickness wound transplanted with NVM+hFF
(c) showed higher αSMA expression in the wound area compared to
NVM+AF (d)
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compared to Acell-NVM at days 7 and 14 (Fig. 5). Fourteen
days post-surgery, the scores of CD8+ lymphocytes of NVM+
hFF and NVM+pFF remained at a similar level as at day 7. At
day 14, no differences in CD8+ lymphocyte scores were ob-
served in wounds treated with NVM+AF in comparison with
Acell-NVM. Interestingly, NVM+hFF (days 7 and 14) and
NVM+pFF (day 14) transplanted wounds showed a higher
CD8+ lymphocyte increase than NVM+AF transplanted
wounds.
Discussion
Fetal dermal cells have been proposed as a potential alterna-
tive cell source replacing autologous cells in cell-based
transplantation therapies. This is largely based on their
multipotency, hypothesized hypo-immunogenicity and high
expansion rate. It is important to gain knowledge about these
fetal dermal cells and their behavior in a wound environment,
before they can be used as cell-based therapy in the clinic.
Most importantly, this study showed that transplantation of
excised full thickness wounds with either NVM+hFF or
NVM+pFF did not improve nor deteriorate scar quality in
comparison to an acellular NVM substitute in the porcine
model after 56 days. Wounds that were transplanted with
NVM containing autologous fibroblasts (AF) demonstrated a
better scar quality 56 days post-surgery than wounds treated
with NVM without cells or with fetal cells. Full-thickness
wounds treated with NVM+AF also resulted in a reduced
wound contraction and αSMA expression in the wound area
Fig. 4 Neutrophil and macrophage influx in full-thickness wounds.
Immune cells were detected with immunohistochemistry and scored
blinded upon grades of influx from 0 (none) to 5 (massive influx). a
Neutrophils were stained with an antibody directed against
myeloperoxidase (MPO). Increased neutrophil scores were observed in
wounds transplanted with NVM+hFF compared to Acell-NVM (&, ˥),
NVM+pFF (‡, Ø) and NVM+AF ($, *) (days 7 and 14). b Influx of
macrophages (antibody MAC 2.48) in wounds was scored per
treatment for post-surgery day 7 and 14. NVM+hFF induced the
macrophage influx in the wound area compared to Acell-NVM (&, ˥,
days 7 and 14) and NVM+AF (*, day 14). Statistical significance
indicated by symbols (Mann–Whitney U test, p<0.05)
Fig. 5 Influx of CD4+ and CD8+ lymphocytes in full-thickness wounds.
The influx of CD4+ and CD8+ lymphocytes in the wounds was scored
blinded for each treatment group (on a scale of 0 (none) to 5 (massive
influx)). a Score of CD4+ lymphocyte influx in the wound area. A
statistically significant higher influx of CD4+ lymphocyte was observed
in wounds transplanted with NVM+hFF compared to Acell-NVM (&, ˥),
and NVM+AF ($, *) (days 7 and 14). b Influx scores of CD8+
lymphocytes infiltrated into the wound area. Higher influx of CD8+
lymphocytes was observed in wounds treated with NVM+hFF or
NVM+pFF in comparison to Acell-NVM (vs. hFF: &, ˥; vs. pFF: <)
and NVM+AF (vs. hFF:$, *; vs. pFF: #). Statistical significance is
indicated with symbols (Mann–Whitney U test, p<0.05)
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compared to NVM+hFF, NVM+pFF and Acell-NVM treat-
ment groups. These findings indicate that fetal dermal cells
behave differently from autologous dermal fibroblasts in ex-
cised full-thickness wounds. Several factors can account for
the different behavior of these multipotent fetal dermal cells.
Possible factors that play a role at an inflammatory level will
be discussed first. Second, we will discuss the influence of
fetal dermal cells on αSMA expression, and finally the limi-
tations of this study.
The increased inflammatory response in wounds
transplanted with either hFFs or pFFs is in contrast to the
described hypo-immunogenic characteristics of (human) fetal
MSCs (Chen et al. 2011; Le Blanc 2003). However, not all
published results seem to support the hypo-immunogenic char-
acteristics of allogeneic MSCs used in transplantations, as
discussed by Griffin et al. (2013) and reported by Nauta et al.
(2006). A possible explanation for the enhanced immune res-
ponse towards xeno-or allo-transplanted fetal dermal cells in
this study could be the induction of a host versus graft immune
response. This is mainly coordinated by T lymphocytes, and in
this study CD4+ and CD8+ lymphocytes tended to be increased
in the treatment with NVM+hFF, and CD8+ lymphocytes also
in the NVM+pFF group. This immune response could be trig-
gered by antigens derived from the transplanted xenogeneic
hFF or allogeneic pFF or MHC expression on these cells in-
duced by the wound environment (Glenn and Whartenby
2014; Singer and Caplan 2011). It has been suggested by
Ren et al. (2008, 2009) that immunosuppressive effects of
MSCs are strongly dependent on their microenvironment.
Glenn et al. (2014) observed that co-culture of active CD8+
lymphocytes with MSCs significantly induced the expression
of MHC class I molecules on MSCs, and MSC cell death.
Furthermore, the presence and concentration of inflammatory
cytokines has been hypothesized to influence the polarization
of MSCs towards a pro-inflammatory (MSC1) or anti-
inflammatory phenotype (MSC2) (Glenn and Whartenby
2014; Singer and Caplan 2011; Wang et al. 2014). The diffe-
rentiation of the fetal dermal cells towards an MSC1 type
might also explain the enhanced inflammatory response. How-
ever, this needs to be further investigated.
In addition to enhanced inflammation in the case of fetal
dermal cells, we observed a significant increase in αSMA
expression in the wound area of the NVM+hFF group com-
pared to NVM+AF at day 14. Similarly, wounds treated with
pFFs showed a slightly elevated αSMA expression in the
wound area in comparison with NVM+AF, but this seemed
to be lower than NVM+hFF. This suggests that the enhanced
or prolonged inflammatory response of fetal fibroblasts in-
duces αSMA expression. Another possibility is that dermal
fetal cells influence αSMA expression and transition to
myofibroblasts by the secretion of growth factors and cyto-
kines. MSCs express TGF-β1 (Barry et al. 2005; Glenn and
Whartenby 2014; Yoon et al. 2010) and can also differentiate
into myofibroblasts in response to TGF-β1 (Glenn and
Whartenby 2014; Kim et al. 2014; Mishra and Banerjee
2011; Popova et al. 2010). Increased myofibroblast numbers
and αSMA expression are hallmarks for fibrosis and scar
formation.
Another reason for the lack of beneficial effects of fetal
dermal cells can be that the survival time of the transplanted
fetal dermal cells is limited. It has been reported that culture-
expanded MSCs (mostly with bone marrow-derived MSCs)
have a short survival time after transplantation (Eggenhofer
et al. 2014; Nuschke 2014) and show little engraftment
(Eggenhofer et al. 2014). A limited survival time of MSCs is
possibly induced by the culture procedure (Eggenhofer et al.
2014) or by a pro-inflammatory wound bed environment
(Nuschke 2014). Effects of the fetal dermis-derived MSCs
can also be dependent on the timing of administration
(Nuschke 2014; Ren et al. 2008; Shi et al. 2010; Wang et al.
2014). In this study, fetal dermal cells were directly
transplanted after excision of the wound. Timing of adminis-
tration is correlated with the wound bed milieu during wound
healing. It has been hypothesized that the immunosuppressive
action of MSCs is induced under highly pro-inflammatory
conditions (Glenn and Whartenby 2014). This suggests that
administration of MSCs at the peak of inflammation during
the wound healing can be more effective.
In this study we were unable to establish beneficial effects
of fetal dermal cells in NVM substitutes onwound healing and
scar formation in a full-thickness porcine wound model in
comparison to STSG, Acell-NVM and NVM+AF. Case re-
ports and a clinical study have reported beneficial effects in
burn wound healing by injection of bone marrow-derived
MSCs (Bey et al. 2010; Lataillade et al. 2007; Rasulov et al.
2005; Rigotti et al. 2007; Sheng et al. 2009). Furthermore,
improved scar quality was observed for hypertrophic burn
scars injected with adipose-derived MSCs (Klinger et al.
2008). In contrast to our study, in those studies MSCs were
directly injected in the area of interest and derived from a
different source, mostly autologous adult MSCs. Differences
in MSC origin and populations have been reviewed by Hass
et al. (2011). In several animal studies, accelerated wound
healing and reduced scar formation were observed when cu-
taneous wounds were transplanted with human MSCs (Stoff
et al. 2009; Xue et al. 2013). However, these studies were
mostly performed in rodent models in which wound healing
is mainly mediated through contraction. The outcomes from
these rodent models are therefore less predictive for the human
wound healing process.
Conclusion
Based on the results obtained in this study, we prefer the use of
AF over that of pFF and hFF in full-thickness wounds to
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restore the dermal tissue function. In the literature, it is de-
scribed that autologous as well as allogeneic MSCs seem to
have great potential in the use of tissue regeneration. Howev-
er, we were unable to prove an additional regenerative capac-
ity of multipotent fetal dermal cells seeded in Novomaix and
transplanted in excised full-thickness wounds. Differences be-
tween fetal dermis-derived MSCs and adult dermis-derived
MSCs, and also between autologous versus allogeneic cells,
should be further investigated before these can be used as a
potential cell source for cell-based therapies. Especially, the
influence of inflamed environments on the polarization of
dermis-derived fetal MSCs towards a pro-inflammatory or
anti-inflammatory phenotype needs to be further elucidated.
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